化学療法誘発性末梢神経障害(Chemotherapy Induced Peripheral Neuropathy):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2014
◆商品コード:GMDHC5827IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年12月10日
◆ページ数:75
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における化学療法誘発性末梢神経障害(Chemotherapy Induced Peripheral Neuropathy)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・化学療法誘発性末梢神経障害(Chemotherapy Induced Peripheral Neuropathy)の概要
・化学療法誘発性末梢神経障害(Chemotherapy Induced Peripheral Neuropathy)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・化学療法誘発性末梢神経障害(Chemotherapy Induced Peripheral Neuropathy)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・化学療法誘発性末梢神経障害(Chemotherapy Induced Peripheral Neuropathy)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・化学療法誘発性末梢神経障害(Chemotherapy Induced Peripheral Neuropathy)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Chemotherapy Induced Peripheral Neuropathy – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Chemotherapy Induced Peripheral Neuropathy – Pipeline Review, H2 2014’, provides an overview of the Chemotherapy Induced Peripheral Neuropathy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Peripheral Neuropathy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chemotherapy Induced Peripheral Neuropathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chemotherapy Induced Peripheral Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chemotherapy Induced Peripheral Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chemotherapy Induced Peripheral Neuropathy Overview 8
Therapeutics Development 9
Pipeline Products for Chemotherapy Induced Peripheral Neuropathy – Overview 9
Pipeline Products for Chemotherapy Induced Peripheral Neuropathy – Comparative Analysis 10
Chemotherapy Induced Peripheral Neuropathy – Therapeutics under Development by Companies 11
Chemotherapy Induced Peripheral Neuropathy – Therapeutics under Investigation by Universities/Institutes 13
Chemotherapy Induced Peripheral Neuropathy – Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Chemotherapy Induced Peripheral Neuropathy – Products under Development by Companies 16
Chemotherapy Induced Peripheral Neuropathy – Products under Investigation by Universities/Institutes 17
Chemotherapy Induced Peripheral Neuropathy – Companies Involved in Therapeutics Development 18
AxoTect, Inc. 18
DARA BioSciences, Inc. 19
Eisai Co., Ltd. 20
Immune Pharmaceuticals, Ltd. 21
Laboratorios Del Dr. Esteve S.A. 22
MAKScientific, LLC 23
Mertiva AB 24
Paladin Labs Inc. 25
Panacea Pharmaceuticals, Inc. 26
PharmatrophiX, Inc. 27
Spectrum Pharmaceuticals, Inc. 28
Spinifex Pharmaceuticals Pty Limited 29
Virobay Inc. 30
Chemotherapy Induced Peripheral Neuropathy – Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
(amitriptyline + ketamine hydrochloride) – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
AK-295 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AL-309 – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AM-1710 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
E-2072 – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
E-52862 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
EMA-401 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Gene Therapy for Chemotherapy Induced Peripheral Neuropathy – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
KRN-5500 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
LM11A-31 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
PAN-811 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
PGN-703 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecule for Chemotherapy Induced Neuropathy – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
SPI-205 – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
VBY-036 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Chemotherapy Induced Peripheral Neuropathy – Recent Pipeline Updates 62
Chemotherapy Induced Peripheral Neuropathy – Dormant Projects 68
Chemotherapy Induced Peripheral Neuropathy – Discontinued Products 69
Chemotherapy Induced Peripheral Neuropathy – Product Development Milestones 70
Featured News & Press Releases 70
Feb 25, 2014: DARA BioSciences’ KRN5500 Receives Orphan Drug Designation From FDA 70
Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program 70
Apr 10, 2012: EpiCept’s AmiKet Receives Fast Track Designation From FDA 71
Mar 28, 2012: Allon Receives US Patent Covering Use Of Its Neuroprotective Technology Platform 72
Feb 07, 2012: EpiCept Files For AmiKet Fast Track Designation 72
Dec 23, 2011: EpiCept Receives FDA Permission To Initiate AmiKet Phase III Clinical Development 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75

[List of Tables]
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2014 9
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Chemotherapy Induced Peripheral Neuropathy - Pipeline by AxoTect, Inc., H2 2014 18
Chemotherapy Induced Peripheral Neuropathy - Pipeline by DARA BioSciences, Inc., H2 2014 19
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Eisai Co., Ltd., H2 2014 20
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals, Ltd., H2 2014 21
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2014 22
Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific, LLC, H2 2014 23
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mertiva AB, H2 2014 24
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Paladin Labs Inc., H2 2014 25
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Panacea Pharmaceuticals, Inc., H2 2014 26
Chemotherapy Induced Peripheral Neuropathy - Pipeline by PharmatrophiX, Inc., H2 2014 27
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 28
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Spinifex Pharmaceuticals Pty Limited, H2 2014 29
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Virobay Inc., H2 2014 30
Assessment by Monotherapy Products, H2 2014 31
Assessment by Combination Products, H2 2014 32
Number of Products by Stage and Target, H2 2014 34
Number of Products by Stage and Mechanism of Action, H2 2014 36
Number of Products by Stage and Route of Administration, H2 2014 38
Number of Products by Stage and Molecule Type, H2 2014 40
Chemotherapy Induced Peripheral Neuropathy Therapeutics - Recent Pipeline Updates, H2 2014 62
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H2 2014 68
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H2 2014 69

[List of Figures]
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2014 9
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Products, H2 2014 15
Assessment by Monotherapy Products, H2 2014 31
Number of Products by Top 10 Targets, H2 2014 33
Number of Products by Stage and Top 10 Targets, H2 2014 33
Number of Products by Top 10 Mechanism of Actions, H2 2014 35
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 36
Number of Products by Top 10 Routes of Administration, H2 2014 37
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 38
Number of Products by Top 10 Molecule Types, H2 2014 39
Number of Products by Stage and Top 10 Molecule Types, H2 2014 40

【掲載企業】

AxoTect, Inc.
DARA BioSciences, Inc.
Eisai Co., Ltd.
Immune Pharmaceuticals, Ltd.
Laboratorios Del Dr. Esteve S.A.
MAKScientific, LLC
Mertiva AB
Paladin Labs Inc.
Panacea Pharmaceuticals, Inc.
PharmatrophiX, Inc.
Spectrum Pharmaceuticals, Inc.
Spinifex Pharmaceuticals Pty Limited
Virobay Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[化学療法誘発性末梢神経障害(Chemotherapy Induced Peripheral Neuropathy):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆